Skip to content
Boost Up Blog – Lifestyle
Author:
EnteroBiotix
EnteroBiotix Announces First Patient Dosed in Phase 2b RISE Study of EBX-102-02 in Irritable Bowel Syndrome with Constipation
July 7, 2026
EnteroBiotix Secures £19m to Initiate Phase 2b Clinical Trial for Irritable Bowel Syndrome
April 29, 2026
Oakworth Capital Inc. Reports Balanced Top Line Growth
April 26, 2026
EnteroBiotix Announces Completion of Enrolment in Phase 2a Trial Evaluating EBX-102-02 Prior to Allogeneic Stem Cell Transplantation
March 10, 2026